Hampton, N.J., USA | March 27, 2026
Celldex Therapeutics reported compelling results from Phase 2 clinical trials of barzolvolimab, demonstrating rapid, profound, and durable improvements in patient quality of life (QoL) across chronic spontaneous urticaria (CSU), cold urticaria (ColdU), and symptomatic dermographism (SD). Presented at the 2026 American Academy of Dermatology (AAD) Annual Meeting, the data highlight the potential of this first-in-class monoclonal antibody targeting mast cells, a key driver of inflammatory and allergic responses. According to the study findings on page 1, improvements were observed across all six Dermatology Life Quality Index (DLQI) domains, reinforcing the therapy’s broad and meaningful impact on daily living, emotional well-being, and functional health outcomes.
Phase 2 Data Demonstrates Rapid and Durable Efficacy
The Phase 2 CSU study showed that up to 51% of patients achieved complete symptom response (UAS7=0) at Week 12, increasing to 71% after 52 weeks of treatment, reflecting deepening efficacy over time. Notably, 41% of patients maintained complete response even seven months after discontinuation, suggesting a disease-modifying effect. As detailed in the clinical analysis on page 1, 94% of patients with well-controlled disease achieved DLQI scores of 0/1, indicating no impact of disease on quality of life, while 76% maintained minimal disease burden post-treatment. These results demonstrate not only strong symptom control but also long-term improvements in patient well-being, addressing a critical unmet need in chronic urticaria management.
Broad Clinical Benefits Across Multiple Urticaria Indications
In additional Phase 2 studies, barzolvolimab showed consistent efficacy across cold urticaria and symptomatic dermographism, with up to 53% and 58% of patients achieving complete response at Week 12, respectively. By Week 20, response rates increased further, highlighting progressive therapeutic benefit. Importantly, improvements in quality of life were rapid, with measurable benefits observed as early as Week 4, and sustained throughout the treatment period. As noted in the data on page 2, treatment led to up to a 4-fold increase in patients achieving DLQI scores of 0/1 compared to placebo, demonstrating broad, clinically meaningful improvements across all QoL domains, including daily activities, work, relationships, and emotional health.
Advertisement
First-in-Class Mechanism Targets Root Cause of Disease
Barzolvolimab operates via a novel mechanism of action, targeting the KIT receptor on mast cells, which are central to the development and progression of chronic urticaria. By inhibiting mast cell activation and survival, the therapy directly addresses the root cause of disease, rather than merely managing symptoms. This mechanism positions barzolvolimab as a potential first-in-class and best-in-disease treatment option, particularly for patients who remain symptomatic despite current therapies.
With global Phase 3 programs already underway, including large-scale trials enrolling nearly 2,000 patients across 43 countries, Celldex is advancing toward potential regulatory approval and broader clinical adoption. The data further support expansion into additional indications such as atopic dermatitis and prurigo nodularis, highlighting the therapy’s broad immunology potential.
Transforming Treatment Landscape for Chronic Urticaria
Chronic urticaria remains a high-burden, underdiagnosed condition associated with severe itching, swelling, psychological distress, and reduced quality of life. Existing treatments often fail to achieve complete symptom control, leaving patients with persistent disease activity and uncertainty. The results presented at AAD 2026 position barzolvolimab as a transformational therapy, capable of delivering rapid symptom relief, sustained disease control, and meaningful improvements in patient quality of life.
By combining innovative biologic targeting, durable clinical efficacy, and patient-centric outcomes, Celldex is helping redefine treatment standards in allergic and inflammatory skin diseases, marking a significant step forward in precision immunology and dermatology care.
Source: Celldex press release
